search
Back to results

Ultrashort GnRH Agonist/Antagonist Versus GnRH Antagonist IVF

Primary Purpose

Infertility

Status
Unknown status
Phase
Phase 2
Locations
Israel
Study Type
Interventional
Intervention
ARM A- Agonist/Antagonist protocol
ARM B- Antagonist protocol
Sponsored by
Sheba Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility focused on measuring GnRH Agonist, GnRH Antagonist, OHSS

Eligibility Criteria

20 Years - 35 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Up to three previous IVF attempts

Exclusion Criteria:

  • Patients with poor or no response in previous COH for IVF cycles
  • Abnormal ovarian reserve test i.e. anti-mullerian hormone (AMH), Antral follicle test
  • Risk factor for Diminished Ovarian Reserve

Sites / Locations

  • Sheba Medical Center- IVF unit

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

ARM A- Agonist/Antagonist protocol

ARM B- Antagonist protocol

Arm Description

The Ultrashort GnRH Agonist/antagonist method entails pre-treatment with oral contraceptive pills before the combination of GnRH ultrashort agonist and antagonist protocol

The standard IVF method entails Flexible Multidose GnRH Antagonist protocol during COH

Outcomes

Primary Outcome Measures

Ongoing pregnancy rates

Secondary Outcome Measures

Total gonadotropin use
Biochemical pregnancy
Positive pregnancy test without documentation of intrauterine or extrauterine pregnancy
Clinical pregnancy
Positive pregnancy test with documentation of intrauterine or extrauterine pregnancy
Multiple pregnancy rate
Miscarriage rate
Fertilization rate
Number of oocytes
OHSS rates
Embryo quality
Grading of a day 3 embryo based on the number of cells that make up the embryo, the amount of fragmentation, and the symmetry of each of the embryo's cells (blastomeres). E.g. good quality embryos: embryos that reach the eight-cell stage with less than 20% fragmentation on day 3

Full Information

First Posted
June 2, 2014
Last Updated
June 23, 2014
Sponsor
Sheba Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT02173977
Brief Title
Ultrashort GnRH Agonist/Antagonist Versus GnRH Antagonist IVF
Official Title
Ultrashort Flare GnRH Agonist Combined With Flexible Multidose GnRH Antagonist Versus Flexible Multidose GnRH Antagonist for Good-prognosis IVF Patients
Study Type
Interventional

2. Study Status

Record Verification Date
June 2014
Overall Recruitment Status
Unknown status
Study Start Date
June 2014 (undefined)
Primary Completion Date
May 2016 (Anticipated)
Study Completion Date
May 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sheba Medical Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the appropriate controlled ovarian hyperstimulation (COH) protocol in good prognosis patients undergoing IVF treatment. The stimulation characteristics of cycles which include ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist will be compared to the flexible multidose GnRH antagonist protocol. The investigators hypothesized that combining the stimulatory effect of GnRH agonists and immediate suppression of the GnRH antagonist in a unique protocol may be a valuable new COH strategy for IVF patients, resulting in improved ART outcome.
Detailed Description
The ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist protocol during COH cycle resulted in a significantly higher clinical pregnancy rate in patients with poor embryo quality, with repeated IVF failures and in poor responders. This protocol combines the effect of the microdose flare on endogenous follicle stimulating hormone (FSH) release with the benefit of an immediate luteinizing hormone suppression of the GnRH antagonist. The basic hypothesis of this approach can also benefit IVF patients with good prognosis without compromising the ability to use gonadotrophin-releasing hormone (GnRH) agonist to effectively trigger ovulation, while completely eliminating any threat of clinically significant ovarian hyperstimulation syndrome (OHSS). The purpose of the study is to compare cycles consisting of ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist with those using the flexible multidose GnRH antagonist protocol 1. To compare the IVF outcome variables and ongoing pregnancy rates.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility
Keywords
GnRH Agonist, GnRH Antagonist, OHSS

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ARM A- Agonist/Antagonist protocol
Arm Type
Active Comparator
Arm Description
The Ultrashort GnRH Agonist/antagonist method entails pre-treatment with oral contraceptive pills before the combination of GnRH ultrashort agonist and antagonist protocol
Arm Title
ARM B- Antagonist protocol
Arm Type
Active Comparator
Arm Description
The standard IVF method entails Flexible Multidose GnRH Antagonist protocol during COH
Intervention Type
Other
Intervention Name(s)
ARM A- Agonist/Antagonist protocol
Intervention Description
In vitro fertilization (IVF/ICSI)
Intervention Type
Other
Intervention Name(s)
ARM B- Antagonist protocol
Intervention Description
In vitro fertilization (IVF/ICSI)
Primary Outcome Measure Information:
Title
Ongoing pregnancy rates
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Total gonadotropin use
Time Frame
2 Years
Title
Biochemical pregnancy
Description
Positive pregnancy test without documentation of intrauterine or extrauterine pregnancy
Time Frame
2 Years
Title
Clinical pregnancy
Description
Positive pregnancy test with documentation of intrauterine or extrauterine pregnancy
Time Frame
2 Years
Title
Multiple pregnancy rate
Time Frame
2 Years
Title
Miscarriage rate
Time Frame
2 Years
Title
Fertilization rate
Time Frame
2 Years
Title
Number of oocytes
Time Frame
2 years
Title
OHSS rates
Time Frame
2 Years
Title
Embryo quality
Description
Grading of a day 3 embryo based on the number of cells that make up the embryo, the amount of fragmentation, and the symmetry of each of the embryo's cells (blastomeres). E.g. good quality embryos: embryos that reach the eight-cell stage with less than 20% fragmentation on day 3
Time Frame
2 Years
Other Pre-specified Outcome Measures:
Title
Positive Pregnancy Test
Time Frame
2 Years

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Up to three previous IVF attempts Exclusion Criteria: Patients with poor or no response in previous COH for IVF cycles Abnormal ovarian reserve test i.e. anti-mullerian hormone (AMH), Antral follicle test Risk factor for Diminished Ovarian Reserve
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Raoul Orvieto, MD
Organizational Affiliation
Infertility & IVF Unit, Dept. Obstetrics & Gynecology - Director
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sheba Medical Center- IVF unit
City
Ramat Gan
ZIP/Postal Code
52621
Country
Israel

12. IPD Sharing Statement

Citations:
PubMed Identifier
18675974
Citation
Orvieto R, Nahum R, Rabinson J, Gemer O, Anteby EY, Meltcer S. Ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist for patients with repeated IVF failures and poor embryo quality. Fertil Steril. 2009 Apr;91(4 Suppl):1398-400. doi: 10.1016/j.fertnstert.2008.04.064. Epub 2008 Aug 3.
Results Reference
background
PubMed Identifier
22840381
Citation
Orvieto R. The ultrashort flare GnRH-agonist/GnRH-antagonist protocol enables cycle programming and may overcome the "detrimental effect" of the oral contraceptive. Fertil Steril. 2012 Sep;98(3):e17-8; author reply e19. doi: 10.1016/j.fertnstert.2012.06.053. Epub 2012 Jul 26. No abstract available.
Results Reference
background
PubMed Identifier
22857268
Citation
Orvieto R, Nahum R, Zohav E, Liberty G, Anteby EY, Meltcer S. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol. Gynecol Endocrinol. 2013 Jan;29(1):51-3. doi: 10.3109/09513590.2012.705376. Epub 2012 Aug 3.
Results Reference
background
PubMed Identifier
20451192
Citation
Orvieto R, Meltcer S, Liberty G, Rabinson J, Anteby EY, Nahum R. A combined approach to patients with repeated IVF failures. Fertil Steril. 2010 Nov;94(6):2462-4. doi: 10.1016/j.fertnstert.2010.03.057. Epub 2010 May 7.
Results Reference
background
PubMed Identifier
17681292
Citation
Orvieto R, Kruchkovich J, Rabinson J, Zohav E, Anteby EY, Meltcer S. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs. Fertil Steril. 2008 Jul;90(1):228-30. doi: 10.1016/j.fertnstert.2007.06.022. Epub 2007 Aug 6.
Results Reference
background

Learn more about this trial

Ultrashort GnRH Agonist/Antagonist Versus GnRH Antagonist IVF

We'll reach out to this number within 24 hrs